Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PLCB1
REST API REST API
Homo sapiens
PLCB1 is differentially expressed in 317 experiments: 158 organism parts: amygdala, bone marrow, ... (156 more);, 207 disease states: normal, control, ... (205 more);, 105 cell types 437 cell lines 43 compound treatments and 85 other conditions.
Synonyms PLC154, PLC-I, KIAA0581
Orthologs PLCB1 (Gallus gallus)   PLCB1 (2 of 2) (Danio rerio)   Plcb1 (Rattus norvegicus)   Plcb1 (Mus musculus)   PLCB1_BOVIN (Bos taurus)   PLCB1 (1 of 2) (Danio rerio)   PLC1 (Saccharomyces cerevisiae)   Plc21C (Drosophila melanogaster)   plcb1 (Xenopus laevis)   PLCB1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, negative regulation of transcription, DNA-dependent, protein binding, nuclear speck, cytoplasm, nuclear chromatin, memory, lamin binding, insulin-like growth factor receptor signaling pathway, membrane fraction, signal transducer activity, positive regulation of JNK cascade, learning, G1 phase, phospholipase C activity, calmodulin binding, GTPase activator activity, synaptic transmission, lipid metabolic process, nucleus, phosphatidylinositol-4,5-bisphosphate binding, G2/M transition of mitotic cell cycle, lipid catabolic process, regulation of G-protein coupled receptor protein signaling pathway, protein homodimerization activity, hydrolase activity, phosphatidylinositol metabolic process, enzyme binding, signal transduction, positive regulation of transcription, DNA-dependent, calcium ion binding, positive regulation of GTPase activity, positive regulation of embryonic development, response to organic nitrogen, positive regulation of myoblast differentiation, interleukin-1-mediated signaling pathway, cerebral cortex development, fat cell differentiation, positive regulation of interleukin-12 production, muscarinic acetylcholine receptor signaling pathway, glutamate signaling pathway, response to peptide hormone stimulus, positive regulation of developmental growth, intracellular signal transduction, phosphatidylinositol phospholipase C activity, CD24 biosynthetic process, regulation of fertilization, interleukin-12-mediated signaling pathway, activation of meiosis involved in egg activation, interleukin-15-mediated signaling pathway, positive regulation of acrosome reaction, negative regulation of monocyte extravasation, response to monosaccharide stimulus
InterPro Term PLC-beta, PLC-beta_CS, C2_Ca-dep, PLipase_C_PInositol-sp_X_dom, C2_membr_targeting, PLC-beta_C, PLipase_C_EF-hand-like, Pinositol_PLipase_C, PLipase_C_Pinositol-sp_Y
UniProt Accession Q9NQ66, Q8IV91, Q8IV92, B1AK73, E9PEL1
Gene-Disease Assocation EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 12; EIEE12
Search EB-eye ENSG00000182621
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (47 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
BT474
2
E-MEXP-440, E-MTAB-37
Jurkat
2
E-MEXP-2197, E-GEOD-1880
K562
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
431 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-MEXP-70, ... (49 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
stromal cell
1
2
E-MEXP-2034, E-GEOD-1460, E-GEOD-10797
NK cell
1
E-GEOD-3982
CD19+ B cell
1
E-MEXP-1600
CD34 positive
1
E-GEOD-12662
fetal RPE
1
E-GEOD-18811
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-MTAB-62, E-MTAB-680, ... (59 experiments)

Factor Value U/D Experiments
control
5
E-GEOD-21912, E-GEOD-20295, E-GEOD-8121, E-GEOD-16363, E-GEOD-20602 ... (5 experiments)
glioblastoma
4
E-GEOD-4290, E-MTAB-62, E-GEOD-4412, E-MEXP-567
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
juvenile dermatomyositis
2
E-MTAB-62, E-GEOD-3307
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
201 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
none
5
6
E-GEOD-5824, E-GEOD-5099, E-GEOD-20719, E-MEXP-1601, E-GEOD-412, ... (11 experiments)
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
LDL
1
E-GEOD-5741
FCCP
1
E-MEXP-2285
M-CSF
1
E-GEOD-5099
37 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
84
2
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-20499, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, E-MEXP-2280, ... (11 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-18005, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-GEOD-12773, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (37 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-548, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.348 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM